One-year follow-up of a TRASER clinical trial for the treatment of nasal telangiectasias

Lasers Surg Med. 2018 Jan;50(1):61-63. doi: 10.1002/lsm.22765. Epub 2017 Nov 24.


Objectives: To evaluate the long-term efficacy of treating nasal telangiectasias with the TRASER device.

Methods: Subjects from the TRASER efficacy analysis clinical trial were invited for a 1-year follow-up. Standardized photographs were taken to compare to baseline. The same clinical trial evaluator graded the subjects' current vessel clearance using the 5-point telangiectasia scale. The data was compiled and analyzed.

Results: Of the subjects with available follow-up data, 44% maintained "complete vessel clearance," 44% dropped down one grade to "almost complete vessel clearance," and 11% dropped down to "moderately clear vessel clearance." All showed clinically significant improvement in nasal telangiectasias from baseline.

Conclusions: The TRASER effectively treats nasal telangiectasias with minimal to mild recurrence at 1-year follow-up. Lasers Surg. Med. 50:61-63, 2018. © 2017 Wiley Periodicals, Inc.

Keywords: TRASER; laser; telangiectasias; vessels.

Publication types

  • Clinical Trial

MeSH terms

  • Follow-Up Studies
  • Humans
  • Lasers, Dye / therapeutic use*
  • Nose*
  • Telangiectasis / pathology
  • Telangiectasis / radiotherapy*
  • Time Factors
  • Treatment Outcome